SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

A New York-based start-up company wants to use batteries to reduce stress on the energy grid and put money back in the pockets of state residents.

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

NASA official says agency innovations in rocket propulsion, AI, and testing infrastructure could could support Golden Dome missile defense initiative ...

The Centers for Medicare & Medicaid Services will use AI to help make prior authorization decisions.

There are more than 198,000 students in the School District of Philadelphia, and nearly a quarter of them rely on SEPTA to get to class.